How gene therapy is emerging from its ‘dark age’
By Gemma Conroy,
Nature
| 12. 14. 2022
In a landmark 1972 paper1, physician Theodore Friedmann and biochemist Richard Roblin foresaw a future in which DNA could be manipulated to help treat human genetic diseases. But they cautioned that it should remain off-limits until the field gained a firmer grasp of genetic processes in cells, their relationship to disease and the potential side effects of treatments.
Over the following years, scientists began to remove these obstacles, and in 1990 achieved a major breakthrough when a four-year-old girl with a form of severe combined immunodeficiency disease was successfully treated in a clinical trial2. This ushered in a decade of high hopes and bold promises.
But the afterglow of that early achievement proved short-lived, as a labyrinth of technical challenges emerged. A common gene-therapy approach involves delivering a healthy gene to cells that have only defective copies in their genetic libraries. Once inside, the therapeutic gene instructs the cells to manufacture functional proteins instead of faulty ones. One difficulty has been making sure a treatment gene zeroes in on the correct cells in the right tissue, and is shuttled into...
Related Articles
Reproductive rights have been a flashpoint in national politics for decades, with the stakes surging after the Supreme Court shredded the right to an abortion. In the current presidential campaign, the battle over abortion has swelled and morphed to encompass in vitro fertilization (IVF), which has now moved rapidly from widely accepted to partisan hot button.
This dramatic shift was highlighted by the February decision of the Alabama Supreme Court that granted personhood rights to frozen IVF embryos, signaling that...
By Annalee Armstrong, BioSpace | 09.11.2024
Complex gene therapies are starting to hit the market but all have faced the same reality: a tepid reception from the healthcare system and a cloudy path to profitability.
It can take about a year for a patient to go...
By Julia Brown, The Conversation | 08.16.2024
With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and...
By Smriti Mallapaty, Nature | 09.11.2024
Under his microscope, Jun Wu could see several tiny spheres, each less than 1 millimetre wide. They looked just like human embryos: a dark cluster of cells surrounded by a cavity, and then another ring of cells.
But Wu, a...